Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis
Drug Design Development and Therapy2018Vol. Volume 12, pp. 1685–1695
Citations Over TimeTop 1% of 2018 papers
Dan Liu, Xiaodan Li, Yonggang Zhang, Joey S.W. Kwong, Ling Li, Yiyi Zhang, Chang Xu, Qianrui Li, Xin Sun, Haoming Tian, Sheyu Li
Abstract
Our results suggested that CQ/HCQ was associated with a reduced risk of CVD in patients with rheumatic diseases. Randomized trials are needed to confirm the potential of CQ/HCQ in cardiovascular prevention in patients with and without rheumatic diseases.
Related Papers
- → Chloroquine and hydroxychloroyuine therapy in rheumatoid arthritis(1962)45 cited
- → Chloroquine and Hydroxychloroquine could be an Available Weapons to Treat COVID-19 Associated Pneumonia(2020)3 cited
- → Chloroquine, hydroxychloroquine, and COVID-19, the Libyan prospective(2020)1 cited
- → Do Chloroquine and Hydroxychloroquine Treat COVID-19?(2021)
- → Do Chloroquine and Hydroxychloroquine Treat COVID-19?(2021)